Sparc and methods of use thereof
AssigneeAbraxis BioScience, LLC
InventorsVuong Trieu, Neil Desai, Patrick Soon-Shiong
Life of this patent
Estimating the term…
Abstract
The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
Claims74
A method for predicting the response of a mammalian tumor to a chemotherapeutic agent or other anticancer agent comprising
- a. isolating a biological sample from the mammal,
- b. detecting the expression of SPARC protein or RNA in the biological sample, and
- c. quantifying the amount of SPARC protein or RNA in the biological sample.
A method of treating a tumor in a mammal with a chemotherapeutic agent or other anticancer agent comprising:
- a. isolating a biological sample from the mammal,
- b. detecting the expression of SPARC protein or RNA in the biological sample,
- c. quantifying the amount of SPARC protein or RNA in the biological sample,
- d. determining if the SPARC protein or RNA is present at a level indicating the administration of the chemotherapeutic agent or other anticancer agent to the mammal, and
- e. administering to the mammal a therapeutically effective amount of the chemotherapeutic agent or other anticancer agent.
A kit for predicting the response of a mammalian tumor to a chemotherapeutic agent or other anticancer agent, comprising
- a. a means for the isolation of protein from the tumor,
- b. a SPARC protein detection and quantification means,
- c. control proteins, and
- d. rules for predicting the response of the tumor.
A kit for predicting the response of a mammalian tumor to a chemotherapeutic agent or other anticancer agent, comprising
- a. a means for the isolation of RNA from the tumor,
- b. a SPARC RNA detection and quantification means,
- c. control RNAs, and
- d. rules for predicting the response of the tumor based on the level of SPARC RNA in tumor.
A method for delivering a therapeutic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic agent coupled to a compound capable of binding an albumin-binding protein and a pharmaceutically acceptable carrier, provided that the pharmaceutical composition does not comprise more than 50% of the therapeutic agent in nanoparticle form.
A method for delivering a chemotherapeutic agent to a tumor in a mammal, wherein the method comprises administering to a mammal a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a chemotherapeutic agent coupled to a SPARC protein capable of binding albumin and a phai inaceutically acceptable carrier.
Dependencies are inferred from the claim text.